MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Long-term Debt
Borrowings due after more than one year.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Long-term Debt · Q3 FY2026 · quarter ended Sep 2026
Long-term debt remains negative
Q3 FY2026 long-term debt was $0, compared with $0 a year earlier.
Context
- Long-term debt amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Long-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 424K USD
- Year-over-year change
- —
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 424K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Long-term Debt vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
- Long-term debt amounts to 0.0% of total assets for MBX, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €377.65M EUR | +14.0% | +59.2% | 15.6% | |
| Mar 2026 | $34.51M USD | — | — | 10.3% | |
| Mar 2026 | $31.06M USD | -85.7% | -44.8% | 7.9% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $9.17M USD | — | — | 0.8% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $0 USD | — | — | 0.0% |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding MBX) | — | -35.9% | +7.2% | 0.4% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.